• Home
  •  / Ionis Pharmaceuticals

Ionis Pharmaceuticals

OverviewSuggest Edit

Ionis Pharmaceuticals discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The Company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients.

TypePublic
Founded1989
HQCarlsbad, USMap
Websiteionispharma.com
Employee Ratings3.3More
Overall CultureFMore
View Jobs (17)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)817(+11%)
Job Openings17
Revenue (FY, 2019)$1.1 B(+88%)
Share Price (Nov 2020)$49.1 (-2%)
Cybersecurity ratingAMore

Key People/Management at Ionis Pharmaceuticals

C. Frank Bennett

C. Frank Bennett

Executive Vice President, Chief Scientific Officer
Brett P. Monia

Brett P. Monia

Chief Executive Officer, Director
Onaiza Cadoret-Manier

Onaiza Cadoret-Manier

Executive Vice President, Chief Corporate Development and Commercial Officer
Elizabeth L. Hougen

Elizabeth L. Hougen

Executive Vice President, Finance and Chief Financial Officer
Richard S. Geary

Richard S. Geary

Executive Vice President, Development
Eric E. Swayze

Eric E. Swayze

Executive Vice President, Research
Show more

Ionis Pharmaceuticals Office Locations

Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, US (HQ)
2855 Gazelle Ct
Show all (1)

Ionis Pharmaceuticals Financials and Metrics

Ionis Pharmaceuticals Revenue

Ionis Pharmaceuticals's revenue was reported to be $1.12 b in FY, 2019
USD

Revenue (Q3, 2020)

160.1m

Gross profit (Q3, 2020)

157.0m

Gross profit margin (Q3, 2020), %

98.1%

Net income (Q3, 2020)

(43.1m)

EBIT (Q3, 2020)

(36.5m)

Market capitalization (20-Nov-2020)

7.1b

Closing stock price (20-Nov-2020)

49.1

Cash (30-Sept-2020)

633.1m

EV

6.5b
Ionis Pharmaceuticals's current market capitalization is $7.1 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

108.5m99.1m102.0m147.3m214.2m283.7m346.6m507.7m599.7m1.1b

Revenue growth, %

45%32%22%

Cost of goods sold

1.8m4.4m

Gross profit

597.9m1.1b
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

23.5m28.6m21.1m24.8m20.7m23.2m47.3m11.6m43.4m38.1m23.6m28.2m57.1m44.1m62.6m120.4m49.1m36.9m38.5m110.9m110.3m104.2m120.9m144.4m117.7m145.4m297.2m163.8m167.9m133.4m145.5m160.1m

Cost of goods sold

1.0m1.4m967.0k2.5m3.0m3.1m

Gross profit

296.2m162.4m166.9m130.8m142.5m157.0m

Gross profit Margin, %

100%99%99%98%98%98%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

70.1m65.5m124.5m160.0m143.0m128.8m84.7m129.6m278.8m683.3m

Accounts Receivable

51.1m

Prepaid Expenses

7.1m5.4m8.7m7.5m15.7m14.8m72.3m102.5m139.8m

Inventories

7.5m8.6m18.2m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

46.0m100.1m86.2m85.0m55.3m56.4m85.6m84.6m107.7m296.5m256.4m161.8m94.1m73.2m148.3m119.5m126.6m93.3m112.5m84.3m114.2m133.0m159.2m227.5m805.5m479.9m375.8m272.5m247.9m486.2m530.2m633.1m

Prepaid Expenses

7.0m6.3m7.4m7.6m7.6m7.4m5.7m7.8m8.1m5.8m7.4m9.8m8.6m8.4m13.2m29.9m29.1m17.4m17.3m15.2m25.9m51.5m48.9m62.1m77.0m97.1m98.7m102.1m118.8m

Inventories

8.4m11.1m19.4m22.9m

Current Assets

536.9m507.6m437.4m410.7m377.1m347.6m350.4m361.6m431.8m669.1m763.3m722.1m705.8m681.2m835.4m855.5m868.3m763.9m698.0m730.3m962.4m964.4m1.1b1.1b2.1b2.1b2.4b2.4b2.4b2.6b2.5b2.5b
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(61.3m)(84.8m)(65.5m)(60.6m)(39.0m)(88.3m)(86.6m)(17.3m)215.0m303.3m

Depreciation and Amortization

4.8m6.6m7.1m6.6m6.4m7.0m7.5m6.7m12.5m14.5m

Inventories

284.0k(1.7m)(2.0m)(1.9m)1.7m(609.0k)(590.0k)(2.5m)1.4m(5.4m)

Accounts Payable

1.3m875.0k1.3m66.0k4.8m9.2m(10.7m)1.8m(655.0k)(16.3m)
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(34.8m)(47.3m)(20.0m)(37.9m)(64.8m)(24.0m)(25.2m)(62.8m)(1.7m)(11.8m)(31.3m)(43.4m)(70.0m)(16.7m)18.9m(16.8m)(62.9m)(119.8m)(112.4m)3.5m(7.7m)(12.6m)(10.8m)(67.4m)(87.7m)90.9m80.9m99.3m(58.5m)(102.2m)(145.3m)

Depreciation and Amortization

1.6m3.1m4.8m1.6m3.4m5.2m1.8m3.7m5.6m2.0m4.0m6.1m2.4m4.9m7.7m3.5m7.2m10.5m3.7m7.4m11.2m

Inventories

496.0k257.0k948.0k(549.0k)(492.0k)(293.0k)379.0k(769.0k)(2.4m)688.0k985.0k(962.0k)922.0k915.0k1.6m(2.5m)(5.7m)(6.6m)(2.2m)(3.0m)(1.5m)

Accounts Payable

(2.6m)2.0m1.4m(2.7m)(8.2m)862.0k(11.4m)(12.4m)(15.2m)472.0k(10.0m)(1.7m)(13.1m)(14.2m)(13.6m)(17.2m)(16.1m)(18.8m)411.0k(14.9m)(11.0m)
show all
USDQ2, 2010

Financial Leverage

2.3 x
Show all financial metrics

Ionis Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

Learn more about our premium products
SecurityScorecard logo

Ionis Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Ionis Pharmaceuticals Online and Social Media Presence

Ionis Pharmaceuticals's Trends

Embed Graph

Ionis Pharmaceuticals Company Culture

  • Overall Culture

    F

    45/100

  • CEO Rating

    D-

    60/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Ionis Pharmaceuticals News and Updates

August 31, 2020

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

CARLSBAD, Calif. and BOSTON, Aug. 31, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares...
August 26, 2020

Ionis Pharmaceuticals to hold cardio-renal franchise webcast

CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise. The approximately 90-minute webcast will include...
June 05, 2020

Ionis Pharmaceuticals to present at upcoming virtual investor conferences

CARLSBAD, Calif., June 5, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences: William Blair 40th Annual Growth Stock Conference...
October 29, 2019

What Caused The Sell-Off In Ionis Pharmaceuticals Stock?

Ionis Pharmaceuticals (NASDAQ: IONS), a pharma company engaged in discovering and developing RNA-targeted therapeutics, has seen its stock decline by about 11% over the last week, trading at levels of around $55 currently. The decline is possibly due to a delay in the release of data...
October 22, 2019

Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast

CARLSBAD, Calif., Oct. 22, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business...
June 06, 2019

Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders

CARLSBAD, Calif., June 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Stanley T. Crook, M.D., Ph.D., chairman of the board and chief executive officer, will present a general corporate update and 30-year retrospective in conjunction with its 2019...
Show more

Ionis Pharmaceuticals Blogs

November 23, 2020

Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development Content Import Mon, 11/23/2020 - 17:16 Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development …
November 12, 2020

Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020

Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020 Content Import Thu, 11/12/2020 - 07:05 Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association …
November 10, 2020

Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference

Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference Content Import Tue, 11/10/2020 - 07:05 Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference November 10, 2020 at 7:05 AM EST …
November 06, 2020

Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes

BOSTON & CARLSBAD, Calif. --(BUSINESS WIRE)--Nov. 6, 2020-- Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics , today recognize the 3 rd annual Familial Chylomicronemia Syndrome (FCS) Awareness Day, a global observance held each year on the first Friday in
November 04, 2020

Ionis reports third quarter 2020 financial results and recent business achievements

On track to achieve 2020 financial guidance   Akcea acquisition supports Ionis' commercial strategy   Webcast today, November 4, 2020, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Nov. 4, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the
October 22, 2020

Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial

- Trial will evaluate ION541 (BIIB105) for treatment of most forms of ALS regardless of family history   - Tofersen and IONIS-C9Rx also currently in clinical trials targeting genetic forms of the disease CARLSBAD, Calif. , Oct. 22, 2020 /PRNewswire/ --  Ionis Pharmaceuticals, Inc.
Show more

 Ionis Pharmaceuticals Frequently Asked Questions

  • When was Ionis Pharmaceuticals founded?

    Ionis Pharmaceuticals was founded in 1989.

  • Who are Ionis Pharmaceuticals key executives?

    Ionis Pharmaceuticals's key executives are C. Frank Bennett, Brett P. Monia and Onaiza Cadoret-Manier.

  • How many employees does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 817 employees.

  • What is Ionis Pharmaceuticals revenue?

    Latest Ionis Pharmaceuticals annual revenue is $1.1 b.

  • What is Ionis Pharmaceuticals revenue per employee?

    Latest Ionis Pharmaceuticals revenue per employee is $1.4 m.

  • Who are Ionis Pharmaceuticals competitors?

    Competitors of Ionis Pharmaceuticals include Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals and Regulus Therapeutics.

  • Where is Ionis Pharmaceuticals headquarters?

    Ionis Pharmaceuticals headquarters is located at 2855 Gazelle Ct, Carlsbad.

  • Where are Ionis Pharmaceuticals offices?

    Ionis Pharmaceuticals has an office in Carlsbad.

  • How many offices does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 1 office.